Common Genomic Response in Different Mouse Models of β -Adrenergic-Induced Cardiomyopathy

Circulation

Volumn 108, Issue 23, 2003, Pages 2926-2933

  Gaussin, Vinciane ^a   Tomlinson, James E ^b   Depre, Christophe ^a   Engelhardt, Stefan ^c   Antos, Christopher L ^d   Takagi, Gen ^a   Hein, Lutz ^c   Topper, James N ^b   Liggett, Stephen B ^e   Olson, Eric N ^d   Lohse, Martin J ^c   Vatner, Stephen F ^a   Vatner, Dorothy E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Genomics; Receptors, adrenergic, beta

Indexed keywords

ANKYRIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; MYOSIN HEAVY CHAIN; UNCOUPLING PROTEIN 2;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOMYOPATHIES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EPINEPHRINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HEART FAILURE, CONGESTIVE; HOMEODOMAIN PROTEINS; ION CHANNELS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, TRANSGENIC; MITOCHONDRIAL PROTEINS; MODELS, ANIMAL; RECEPTORS, ADRENERGIC, BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0345167075     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000101922.18151.7B     Document Type: Article

References (32)

1. Gaudin C, Ishikawa Y, Wight DC, et al. Overexpression of Gs alpha protein in the hearts of transgenic mice. J Clin Invest. 1995;95:1676-1683.
2. Geng YJ, Ishikawa Y, Vatner DE, et al. Apoptosis of cardiac myocytes in Gsalpha transgenic mice. Circ Res. 1999;84:34-42.
3. Engelhardt S, Hein L, Wiesmann F, et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059-7064.
4. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-830.
5. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 1994;264:582-586.
6. Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707-1714.
7. Antos CL, Frey N, Marx SO, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res. 2001;89:997-1004.
8. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-1446.
9. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
10. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94:2793-2799.
11. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191.
12. Green CD, Simons JF, Taillon BE, et al. Open systems: panoramic views of gene expression. J Immunol Methods. 2001;250:67-79.
13. Asai K, Yang GP, Geng YJ, et al. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. J Clin Invest. 1999;104:551-558.
14. Shimkets RA, Lowe DG, Tai JT, et al. Gene expression analysis by transcript profiling coupled to a gene database query. Nat Biotechnol. 1999;17:798-803.
15. Gibson UEM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6:995-1001.
16. Depre C, Shipley GL, Chen W, et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998;4:1269-1275.
17. Depre C, Tomlinson JE, Kudej RK, et al. Gene program for cardiac cell survival induced by transient ischemia in conscious pigs. Proc Natl Acad Sci U S A. 2001;98:9336-9341.
18. Diehl AM, Hoek JB. Mitochondrial uncoupling: role of uncoupling protein anion carriers and relationship to thermogenesis and weight control "the benefits of losing control." J Bioenerg Biomembr. 1999;31:493-506.
19. Lee SM, Tsui SK, Chan KK, et al. Chromosomal mapping, tissue distribution and cDNA sequence of four-and-a-half LIM domain protein 1 (FHL1). Gene. 1998;216:163-170.
20. Chu PH, Ruiz-Lozano P, Zhou Q, et al. Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech Dev. 2000;95:259-265.
21. Degens H, Gilde AJ, Lindhout M, et al. Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. Am J Physiol. 2003;284:H108-H115.
22. Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol. 2001;38:1175-1180.
23. Hwang DM, Dempsey AA, Wang RX, et al. A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. Circulation. 1997;96:4146-4203.
24. Morgan MJ, Madgwick AJ. Slim defines a novel family of LIM-proteins expressed in skeletal muscle. Biochem Biophys Res Commun. 1996;225:632-638.
25. Pauletto P, Dalla Libera L, Vescovo G, et al. Propranolol-induced changes in ventricular isomyosin composition in the rat. Am Heart J. 1985;109:1269-1273.
26. Arsenijevic D, Onuma H, Pecqueur C, et al. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet. 2000;26:435-439.
27. Fleury C, Sanchis D. The mitochondrial uncoupling protein-2: current status. Int J Biochem Cell Biol. 1999;31:1261-1278.
28. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33:887-905.
29. Eckhart AD, Koch WJ. Transgenic studies of cardiac adrenergic receptor regulation. J Pharmacol Exp Ther. 2001;299:1-5.
30. Xiao RP, Cheng H, Zhou YY, et al. Recent advances in cardiac beta(2)-adrenergic signal transduction. Circ Res. 1999;85:1092-1100.
31. Chesley A, Lundberg MS, Asai T, et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res. 2000;87:1172-1179.
32. Rindt H, Gulick J, Knotts S, et al. In vivo analysis of the murine beta-myosin heavy chain gene promoter. J Biol Chem. 1993;268:5332-5338.